Johnson & Johnson vs Marriott International: Strategic Comparison

This in-depth comparison examines Johnson & Johnson and Marriott International across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Johnson & Johnson on its own, evaluating Marriott International, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Johnson & Johnson and Marriott International is widest.

On the headline numbers, Johnson & Johnson reports annual revenue of $94.2B against $26.2B for Marriott International, while their respective market capitalizations stand at $643.9B and $91.5B. Both Johnson & Johnson and Marriott International are headquartered in United States, so they compete in a shared home market and regulatory environment.

Johnson & Johnson: Johnson & Johnson is one of the largest healthcare companies in the world by revenue and market value. Once known for Band-Aid, Tylenol, and baby powder, it moved those consumer brands into Kenvue in 2023 and now reports two segments: Innovative Medicine and MedTech. In 2025 it generated $94.2 billion in sales with about 140,800 employees, and in 2026 it is aiming for more than $100 billion in revenue during its 140th year.

Marriott International: Marriott International, based in Bethesda, Maryland and listed on Nasdaq as MAR, is the largest hotel company in the world by rooms. Its portfolio spans luxury brands such as The Ritz-Carlton, St. Regis, JW Marriott, W Hotels and EDITION; premium brands such as Marriott Hotels, Sheraton and Westin; and select-service brands such as Courtyard, Residence Inn, Fairfield and Moxy. Managed and franchised hotels account for about 99% of its rooms.

Johnson & Johnson and Marriott International pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Johnson & Johnson and Marriott International.

Johnson & Johnson business model: J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal. Margins depend on patent protection, so growth relies on launching new drugs as older ones such as STELARA face biosimilars. MedTech (about 36%, $33.8 billion) sells surgical tools, wound closure, orthopaedic implants, electrophysiology catheters and mapping systems, Abiomed heart pumps, Shockwave lithotripsy devices, and contact lenses to hospitals and surgery centers, with much of the revenue coming from recurring disposables and implants.

Marriott International business model: Marriott makes money mainly from fees. Franchise fees ($3.325B in FY2025) come from owners who license a Marriott brand, reservation system and Bonvoy distribution; this line also includes co-branded credit card and residential branding fees. Base management fees ($1.322B) and incentive management fees ($791M) come from hotels Marriott operates for owners. A much larger cost reimbursement line ($19.204B) passes through property-level and centralized program costs, such as hotel staff at managed properties and loyalty, and largely nets out against matching expenses. Owned, leased and other revenue was $1.679B.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Johnson & Johnson stack up against those of Marriott International.

Johnson & Johnson competitive advantage: J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time. That diversification lets it absorb clinical-trial failures and patent expirations that would sink a single-product biotech, and fund multibillion-dollar acquisitions such as Abiomed, Shockwave Medical, and Intra-Cellular Therapies with cash and investment-grade debt.

Marriott International competitive advantage: Marriott's advantage is scale on both sides of the market. For travelers, Marriott Bonvoy (more than 295 million members by June 2026) and over 30 brands across price points create reasons to book direct. For owners and lenders, that demand engine, plus Marriott's distribution and procurement scale, makes a Marriott flag easier to finance and fill, which feeds a record development pipeline of about 629,000 rooms.

Future prospects matter as much as current results. The growth strategies below explain how Johnson & Johnson and Marriott International each plan to expand from here.

Johnson & Johnson growth strategy: J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025). Internally it is expanding TREMFYA and CAPLYTA labels, advancing multiple myeloma combinations such as TALVEY plus DARZALEX FASPRO, and developing the OTTAVA soft-tissue surgical robot to compete with Intuitive Surgical's da Vinci.

Marriott International growth strategy: Growth comes from adding rooms rather than buying buildings. Marriott signed nearly 1,200 organic deals (about 163,000 rooms) in 2025 and posted record signings in the first half of 2026. Priorities include conversion-friendly brands and collections, midscale expansion (City Express by Marriott, StudioRes, Four Points Flex), luxury and all-inclusive resorts, Homes & Villas by Marriott Bonvoy, and deeper Bonvoy monetization through co-branded cards.

A closer look at the financial trajectory of Johnson & Johnson and Marriott International rounds out the comparison.

Johnson & Johnson: J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.

Marriott International: Marriott reported FY2025 revenue of $26.186 billion and net income of $2.601 billion, with gross fee revenues of $5.438 billion. Because owners fund the hotels, Marriott's capital needs are modest and most cash goes back to shareholders: over $4.0 billion was returned in 2025. In Q2 2026 revenue was $7.071 billion, net income $766 million and adjusted EBITDA $1.592 billion; management raised 2026 guidance to global RevPAR growth of 3% to 3.5%, adjusted EBITDA of $5.97 to $6.03 billion and more than $4.5 billion of capital returns.